Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Swiss National Bank

Swiss National Bank grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 232,800 shares of the medical research company's stock after purchasing an additional 4,900 shares during the period. Swiss National Bank owned approximately 0.18% of Natera worth $36,852,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares during the last quarter. Principal Securities Inc. raised its stake in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Finally, True Wealth Design LLC purchased a new position in Natera in the 3rd quarter worth $57,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, insider John Fesko sold 663 shares of Natera stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the sale, the insider now owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 24,861 shares of Natera stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the sale, the insider now directly owns 140,684 shares in the company, valued at approximately $23,208,639.48. The trade was a 15.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 307,466 shares of company stock valued at $49,047,655 in the last ninety days. 7.60% of the stock is currently owned by corporate insiders.

Natera Price Performance

NTRA traded down $1.24 during trading on Thursday, reaching $149.63. The company's stock had a trading volume of 1,000,664 shares, compared to its average volume of 1,347,583. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a fifty day simple moving average of $162.25 and a two-hundred day simple moving average of $149.27. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00. The company has a market cap of $20.23 billion, a price-to-earnings ratio of -85.02 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NTRA shares. StockNews.com upgraded Natera from a "sell" rating to a "hold" rating in a research note on Wednesday. Canaccord Genuity Group restated a "buy" rating and issued a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. The Goldman Sachs Group raised their target price on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Finally, Piper Sandler increased their price target on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.